Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Molecular testing in thyroid cancer diagnosis and management

Best Practice & Research Clinical Endocrinology & Metabolism(2022)10.1016/j.beem.2022.101680Source: DataRank Database

Molecular testing in thyroid cancer diagnosis and management is a research paper published in Best Practice & Research Clinical Endocrinology & Metabolism (2022). On theSindex it has a DataRank of 0. It has been cited 25 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

25 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)OA: closedTopics (9)IDs (PubMed)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Matthew D. Ringel ORCID,Jennifer A. Sipos ORCID

Live enrichment

PubMed:35691860

National Cancer Institute

Grant: R01CA227847

National Cancer Institute

Grant: R01CA240302

National Institutes of Health

closedLicense: https://doi.org/10.15223/policy-004

publisherhttps://api.elsevier.com/content/article/PII:S1521690X22000677?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1521690X22000677?httpAccept=text/plain

MeSH Terms

HumansThyroid NeoplasmsThyroid NoduleBiopsy, Fine-NeedleMolecular Diagnostic Techniques

Keywords

GenomicsTargeted TherapiesThyroid NodulesKinase Inhibitors

Related Papers (4)

New Horizons: Emerging Therapies and Targets in Thyroid Cancer

The Journal of Clinical Endocrinology & Metabolism(2020)

co-cited

10.1210/clinem/dgaa687

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

N/A

5.1DataRank · unranked

The Lancet Diabetes & Endocrinology(2021)

co-cited

10.1016/s2213-8587(21)00120-0

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

N/A

7.1DataRank · unranked

Annals of Oncology(2022)

co-cited

10.1016/j.annonc.2021.12.014

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

N/A

1.3DataRank · unranked

Science(2017)

co-cited

10.1126/science.aan6733

Molecular testing in thyroid cancer diagnosis and management

FAIR Checklist

Authors (2)

Funding (3 grants)

Open Access

Topics

Related Papers (4)